Trial List
List all clinical trials by discovery date. Accepts regular expressions in search.
GET /trials/?format=api&page=482
{ "count": 4854, "next": "http://api.gregory-ms.com/trials/?format=api&page=483", "previous": "http://api.gregory-ms.com/trials/?format=api&page=481", "results": [ { "trial_id": 47, "title": "Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People", "summary": "Conditions: Autoimmune or Autoinflammatory Diseases; HIV; Multiple Sclerosis; Solid Tumors or Cancers; Solid Organ TransplantIntervention: Other: Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19Sponsor : Assistance Publique - Hôpitaux de ParisNot yet recruiting ", "published_date": "2021-02-04T00:00:00Z", "discovery_date": "2021-04-14T10:53:38Z", "link": "https://clinicaltrials.gov/show/NCT04844489", "source": "WHO XML import", "relevant": null, "identifiers": { "nct": "NCT04844489" }, "categories": [], "export_date": "2024-05-04T00:00:00Z", "internal_number": "12822828", "last_refreshed_on": "2023-02-13", "scientific_title": "Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People", "primary_sponsor": "Assistance Publique - Hôpitaux de Paris", "retrospective_flag": "Yes", "date_registration": null, "source_register": "ClinicalTrials.gov", "recruitment_status": "Not recruiting", "other_records": "No", "inclusion_agemin": "18 Years", "inclusion_agemax": "N/A", "inclusion_gender": "All", "date_enrollement": "2021-04-16", "target_size": "377", "study_type": "Interventional", "study_design": "Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Other. Masking: None (Open Label).", "phase": "N/A", "countries": "France", "contact_firstname": null, "contact_lastname": null, "contact_address": null, "contact_email": null, "contact_tel": null, "contact_affiliation": null, "inclusion_criteria": "<br> Inclusion Criteria:\r<br>\r<br> - Age greater than or equal to 18 years\r<br>\r<br> - Patients eligible for BNT162b2 vaccination\r<br>\r<br> - Immunocompromised patients according to one of the following criteria:\r<br>\r<br> 1. Patients with autoimmune or autoinflammatory diseases treated\r<br>\r<br> 1. For at least three months\r<br>\r<br> 2. Having received at least 0.1 mg / kg / day of prednisone (or equivalent) for\r<br> at least three months\r<br>\r<br> 3. Currently receiving at least 5 mg / day of prednisone in combination with an\r<br> immunosuppressant (methotrexate, cyclosporine, mycophenolate mofetil,\r<br> rapamycin, azathioprine, cyclophosphamide) or biotherapy (anti-B cells\r<br> (rituximab and others) anti-TNF, IL- 1, IL-6R, IL-12/23, IL-17, or B7\r<br> (CTLA4-Ig)) or a kinase inhibitor (Janus, Tyrosine))\r<br>\r<br> 2. HIV-infected patients with a CD4 count <500 / mm3 and a viral load <50 copies /\r<br> ml on stable antiretroviral therapy for at least 3 months\r<br>\r<br> 3. Patients with multiple sclerosis treated with a disease-modifying drug for at\r<br> least 3 months at a stable dose (teriflunomide, dimethyl-fumarate, fingolimod,\r<br> ocrelizumab, rituximab, natalizumab)\r<br>\r<br> 4. Patients with solid tumors or cancers:\r<br>\r<br> 1. Patients who have received active cancer treatment other than chemotherapy\r<br> (targeted therapy, radiotherapy, surgery, hormone therapy) in the previous\r<br> month\r<br>\r<br> 2. Patients who have received active cancer treatment with chemotherapy (alone\r<br> or in combination with immunotherapy, radiotherapy or targeted therapy) in\r<br> the previous month\r<br>\r<br> 3. Patients who have received active oncology treatment with one or more\r<br> immunotherapy (s) in combination with anti-PD1, anti-PD-L1, anti-CTLA4\r<br> antibodies without chemotherapy in the previous month.\r<br>\r<br> 5. Solid organ transplant patients for more than 3 months who have not received a\r<br> depleting T agent in the induction protocol, and for> 6 months otherwise\r<br>\r<br> - Life expectancy of more than 3 months\r<br>\r<br> - Having been informed about the study and having given their written and informed\r<br> consent\r<br>\r<br> - Beneficiaries or beneficiaries of a social security scheme\r<br>\r<br> Exclusion Criteria:\r<br>\r<br> - Patients who may be included in more than one of the sub-cohorts\r<br>\r<br> - Other vaccination received in the 15 days preceding recruitment or planned in the\r<br> month following the second vaccine injection\r<br>\r<br> - Known or suspected allergy to one of the components of the vaccine\r<br>\r<br> - Severe reaction after previous administration of any influenza vaccine (multiple\r<br> sclerosis, Guillain-Barré syndrome)\r<br>\r<br> - Contact subjects of a patient with an undetected documented SARS-CoV-2 infection\r<br>\r<br> - Evocative signs of COVID-19\r<br>\r<br> - History of documented SARS-CoV-2 infection of less than 3 months (RT-PCR, Lamp PCR,\r<br> antigen test)\r<br>\r<br> - Last outbreak of the disease less than 3 months old for patients with Multiple\r<br> Sclerosis; less than a month old for patients with autoimmune or autoinflammatory\r<br> diseases\r<br>\r<br> - For patients with HIV, transient viremia (blip) less than 3 months old\r<br>\r<br> - Intercurrent infection\r<br>\r<br> - For organ transplants, episode of cellular or humoral rejection during the 3 months\r<br> preceding inclusion\r<br>\r<br> - Healthy volunteers\r<br>\r<br> - Pregnancy less than 13 weeks old according to the declaration of pregnancy\r<br>\r<br> - Refusal of participation by the patient\r<br>\r<br> - Patients subject to legal protection measures\r<br>", "exclusion_criteria": null, "condition": "Autoimmune or Autoinflammatory Diseases;HIV;Multiple Sclerosis;Solid Tumors or Cancers;Solid Organ Transplant", "intervention": "Other: Blood samples for the study of the humoral response to SARS-CoV-2 variants and of the cellular response after vaccination against COVID-19", "primary_outcome": "Proportion of patients with a neutralizing antibody titer greater than 1/10 towards the wild strain and the English VOC 202012/01, South African 501Y.V2 variants and any other variants that may emerge", "secondary_outcome": "Proportion of patients with a positive serology by detection of IgG anti-receptor-binding domain (RBD) antibodies to the Spike protein of SARS-CoV-2 measured by the SARS-CoV technique -2 IgG II Quant assay (Abbott);Proportion of patients with a positive serology by detection of the anti-Spike protein IgG antibodies of SARS-CoV-2 measured by the Euroimmun technique;Proportion of patients with positive anti-RBD IgG serology on D0;Anti-RBD IgG level;Antibody neutralization title;Neutralization title for antibodies against the wild strain and to the English VOC 202012/01, South African 501Y.V2 variants and any other variants that could be introduced to emerge.;Supervised and unsupervised analyzes of deep immunophenotyping of T and B lymphocytes;Cytometric measurement of intracellular cytokines (IFN, TNF, IL-2, IL4, IL10, IL-17) after stimulation of T lymphocytes by pools of SARS-CoV-2, CMV, EBV and influenza peptides;Structure and specificity of the TCR (T-cells Receptors) repertoire of blood cells", "secondary_id": "2021-A00469-32;APHP210305", "source_support": "Please refer to primary and secondary sponsors", "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 46, "title": "Effects of Lutein Supplementation on Cognition and MPOD in Multiple Sclerosis Patients-", "summary": "Condition: Multiple SclerosisInterventions: Dietary Supplement: Lutein; Dietary Supplement: PlaceboSponsors : University of Illinois at Urbana-Champaign; Division of Nutritional Sciences, University of Illinois at Urbana-ChampaignRecruiting ", "published_date": "2021-07-04T00:00:00Z", "discovery_date": "2021-04-14T10:53:38Z", "link": "https://clinicaltrials.gov/show/NCT04843813", "source": "WHO XML import", "relevant": null, "identifiers": { "nct": "NCT04843813" }, "categories": [], "export_date": "2024-05-04T00:00:00Z", "internal_number": "10885334", "last_refreshed_on": "2021-04-26", "scientific_title": "Lutein and Multiple Sclerosis Experimental Study (LuMES)", "primary_sponsor": "University of Illinois at Urbana-Champaign", "retrospective_flag": "No", "date_registration": null, "source_register": "ClinicalTrials.gov", "recruitment_status": "Recruiting", "other_records": "No", "inclusion_agemin": "18 Years", "inclusion_agemax": "64 Years", "inclusion_gender": "All", "date_enrollement": "2021-03-26", "target_size": "60", "study_type": "Interventional", "study_design": "Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: Single (Participant).", "phase": "N/A", "countries": "United States", "contact_firstname": "; ;", "contact_lastname": "Naiman Khan, PhD;Naiman Khan, PhD, RD;Naiman A Khan, PhD, RD", "contact_address": null, "contact_email": ";[email protected];[email protected]", "contact_tel": ";217-300-2197;", "contact_affiliation": "University of Illinois Urbana Champaign;", "inclusion_criteria": "<br> Inclusion Criteria:\r<br>\r<br> - 18-64.9 years\r<br>\r<br> - Self-reported relapsing-remitting MS (RRMS) diagnosis\r<br>\r<br> - Expanded Disability Status Scale (EDSS) score between 0-3.5\r<br>\r<br> - Macular Pigment Optical Density at baseline (MPOD =0.35)\r<br>\r<br> - Score =55 during the Symbol Digit Modalities Test (SDMT)\r<br>\r<br> - 20/20 or corrected vision\r<br>\r<br> - No presence of color blindness\r<br>\r<br> - No history of age-related macular degeneration\r<br>\r<br> - No history of epileptic seizures\r<br>\r<br> Exclusion Criteria:\r<br>\r<br> - Under 18 years or over 64.9 years\r<br>\r<br> - MS diagnosis other than RRMS\r<br>\r<br> - Pregnancy\r<br>\r<br> - Uncorrected vision\r<br>\r<br> - Presence of color blindness\r<br>\r<br> - PDDS score of 7 or more\r<br>\r<br> - Prior diagnosis of age-related macular degeneration\r<br>\r<br> - History of epileptic seizures\r<br>", "exclusion_criteria": null, "condition": "Multiple Sclerosis", "intervention": "Dietary Supplement: Lutein;Dietary Supplement: Placebo", "primary_outcome": "Macular Pigment Optical Density;Attentional Accuracy;Attentional Reaction Time;Attentional Resource Allocation;Attentional Processing Speed", "secondary_outcome": null, "secondary_id": "2001-2", "source_support": "Please refer to primary and secondary sponsors", "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 44, "title": "The Effect of Telerehabilitation Based Pilates Training in Multiple Sclerosis Patients", "summary": "Condition: Multiple SclerosisIntervention: Other: Telerehabilitation-based Pilates ExerciseSponsor : Gazi UniversityRecruiting ", "published_date": "2021-03-30T00:00:00Z", "discovery_date": "2021-04-09T13:11:11Z", "link": "https://clinicaltrials.gov/show/NCT04838886", "source": "WHO XML import", "relevant": null, "identifiers": { "nct": "NCT04838886" }, "categories": [ { "category_id": 18, "category_description": "Search terms: telerehabilitation, physical therapy, virtual reality, gamification, neurostimulation, cognitive training, spasticity, motor control.\n\nSuggested by Alejandro Carrabs", "category_name": "Physical therapy and Telerehabilitation", "category_slug": "physical-therapy-and-telerehabilitation", "category_terms": [ "telerehabilitation", "physical therapy", "virtual reality", "gamification", "neurostimulation", "cognitive training", "spasticity", "motor control" ], "article_count": 178 } ], "export_date": "2024-05-04T00:00:00Z", "internal_number": "12343701", "last_refreshed_on": "2022-06-06", "scientific_title": "The Effect of Telerehabilitation Based Pilates Training on Physical Performance and Quality of Life in Multiple Sclerosis Patients", "primary_sponsor": "Gazi University", "retrospective_flag": "Yes", "date_registration": null, "source_register": "ClinicalTrials.gov", "recruitment_status": "Not recruiting", "other_records": "No", "inclusion_agemin": "18 Years", "inclusion_agemax": "65 Years", "inclusion_gender": "All", "date_enrollement": "2021-04-15", "target_size": "30", "study_type": "Interventional", "study_design": "Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Outcomes Assessor).", "phase": "N/A", "countries": "Turkey", "contact_firstname": ";", "contact_lastname": "Kader Eldemir, PT, MSc.;Arzu Güçlü-Gündüz, PT, PhD", "contact_address": null, "contact_email": ";", "contact_tel": ";", "contact_affiliation": "Research Assistant;Professor", "inclusion_criteria": "<br> Inclusion Criteria:\r<br>\r<br> - 18-65 years of age\r<br>\r<br> - Voluntarily participate in research to accept\r<br>\r<br> - Having a diagnosis of \"Multiple Sclerosis\" by a specialist physician\r<br>\r<br> - Relapse free in the last 3 mounts\r<br>\r<br> - An Expanded Disability Status Scale (EDSS) score less than or equal to 4\r<br>\r<br> Exclusion Criteria:\r<br>\r<br> - Any cardiovascular, orthopedic, visual, hearing, and perception problems that may\r<br> affect the results of the research.\r<br>", "exclusion_criteria": null, "condition": "Multiple Sclerosis", "intervention": "Other: Telerehabilitation-based Pilates Exercise", "primary_outcome": "Dynamic Balance- Baseline;Dynamic Balance-Post intervention;Static Balance- Baseline;Static Balance- Post intervention;An individual's confidence in performing activities- Baseline;An individual's confidence in performing activities- Post intervention;Exercise capacity- Baseline;Exercise capacity- Post intervention;Gait parameters- Baseline;Gait parameters- Post intervention;Functional mobility- Baseline;Functional mobility- Post intervention;Core endurance- Baseline;Core endurance- Post intervention;Core strength- Baseline;Core strength-Post intervention;Muscle Strength outcomes- Baseline;Muscle Strength outcomes- Post intervention", "secondary_outcome": "Physical activity level- Baseline;Physical activity level- Post intervention;Fatigue severity- Baseline;Fatigue severity- Post intervention;Impact of fatigue on activities- Baseline;Impact of fatigue on activities- Post intervention;Health related quality of life- Baseline;Health related quality of life- Post intervention- Post intervention", "secondary_id": "Gazi 2", "source_support": "Please refer to primary and secondary sponsors", "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 43, "title": "TELEMS: Feasibility of Remote Patient Visits in MS", "summary": "Condition: Multiple SclerosisInterventions: Other: EDSS; Other: Discussion of symptomsSponsor : Medical University of ViennaRecruiting ", "published_date": "2021-02-21T00:00:00Z", "discovery_date": "2021-04-09T13:11:11Z", "link": "https://clinicaltrials.gov/show/NCT04838990", "source": "WHO XML import", "relevant": null, "identifiers": { "nct": "NCT04838990" }, "categories": [], "export_date": "2024-05-04T00:00:00Z", "internal_number": "11879313", "last_refreshed_on": "2022-01-31", "scientific_title": "TELE MS RCT: A Randomized Controlled Trial to Evaluate Feasibility of Remote Patient Visits in People With Multiple Sclerosis", "primary_sponsor": "Medical University of Vienna", "retrospective_flag": "No", "date_registration": null, "source_register": "ClinicalTrials.gov", "recruitment_status": "Not recruiting", "other_records": "No", "inclusion_agemin": "16 Years", "inclusion_agemax": "80 Years", "inclusion_gender": "All", "date_enrollement": "2020-11-01", "target_size": "45", "study_type": "Interventional", "study_design": "Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Health Services Research. Masking: None (Open Label).", "phase": "N/A", "countries": "Austria", "contact_firstname": "", "contact_lastname": "Patrick Altmann, MD PhD", "contact_address": null, "contact_email": null, "contact_tel": null, "contact_affiliation": "Medical University of Vienna", "inclusion_criteria": "<br> Inclusion Criteria:\r<br>\r<br> - confirmed diagnosis of any type of MS\r<br>\r<br> - own a phone/smartphone/computer\r<br>\r<br> - informed consent\r<br>\r<br> Exclusion Criteria:\r<br>\r<br> - language barriers\r<br>", "exclusion_criteria": null, "condition": "Multiple Sclerosis", "intervention": "Other: EDSS;Other: Discussion of symptoms, Patient reported outcome (MSIS)", "primary_outcome": "TMPQ", "secondary_outcome": "PPSM", "secondary_id": "2157/2020", "source_support": "Please refer to primary and secondary sponsors", "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 38, "title": "Therapeutic Adherence of Multiple Sclerosis Patients", "summary": "Condition: Multiple SclerosisIntervention: Other: Study of the role of sociocognitive factorsSponsor : Lille Catholic UniversityNot yet recruiting ", "published_date": "2021-02-02T00:00:00Z", "discovery_date": "2021-04-08T11:57:29Z", "link": "https://clinicaltrials.gov/ct2/show/NCT04837352", "source": "WHO XML import", "relevant": null, "identifiers": { "nct": "NCT04837352" }, "categories": [], "export_date": "2024-05-04T00:00:00Z", "internal_number": "13875292", "last_refreshed_on": "2024-04-08", "scientific_title": "Obstacles and Levers of the Therapeutic Adherence of Multiple Sclerosis Patients", "primary_sponsor": "Lille Catholic University", "retrospective_flag": "Yes", "date_registration": null, "source_register": "ClinicalTrials.gov", "recruitment_status": "Recruiting", "other_records": "No", "inclusion_agemin": "18 Years", "inclusion_agemax": "N/A", "inclusion_gender": "All", "date_enrollement": "2022-01-18", "target_size": "153", "study_type": "Observational", "study_design": null, "phase": null, "countries": "France", "contact_firstname": ";", "contact_lastname": "Bruno Lenne;Marie-Paule Lebitasy, MD, PhD", "contact_address": null, "contact_email": ";[email protected]", "contact_tel": ";03.20.22.52.69", "contact_affiliation": "Hôpital Saint Vincent de Paul, Lille;", "inclusion_criteria": "<br> Inclusion Criteria:\r<br>\r<br> - Multiple sclerosis defined according to McDonald criteria;\r<br>\r<br> - Already undergone or beginning substantive treatment (self-managed, excluding\r<br> treatment administered in hospital)\r<br>\r<br> - Aged = 18 years;\r<br>\r<br> - Given the informed consent form.\r<br>\r<br> Exclusion Criteria:\r<br>\r<br> - Severe cognitive impairment (score below the 5th percentile);\r<br>\r<br> - Any associated neurological pathology or serious or chronic somatic disease (cancer);\r<br>\r<br> - Being under a legal protection measure.\r<br>", "exclusion_criteria": null, "condition": "Multiple Sclerosis", "intervention": "Other: Study of the role of sociocognitive factors", "primary_outcome": "Therapeutic adherence evaluated by a Likert scale", "secondary_outcome": "Perceived threat measured with a self-assessment form;Perceived interpersonal relationships quality measure by the perceived social support questionnaire (QSSP);Perceived interpersonal relationships quality measure by the 4-Point ordinal Alliance Scale (11-items 4-PAS);Illness duration in days;Handicap will be evaluated by the Expanded Disability Status Scale (EDSS);Relapses number;Fatigue perceived through the FSS (Fatigue Severity Scale);Cognitive disorders through the SDMT (Symbol Digit Modalities Test);Anxiety-depressive symptoms measured by the Hospital Anxiety and Depression Scale (HADS);Personality traits measured by the Big Five Inventory-FR questionnaire (BFI-FR)", "secondary_id": "RC-P00105", "source_support": "Please refer to primary and secondary sponsors", "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 39, "title": "Impact of Neuropsychological Disorders in Multiple Sclerosis", "summary": "Condition: Multiple SclerosisIntervention: Other: Three dimensional gait analysis with eyetrackingSponsor : Lille Catholic UniversityNot yet recruiting ", "published_date": "2021-07-04T00:00:00Z", "discovery_date": "2021-04-08T11:57:29Z", "link": "https://clinicaltrials.gov/show/NCT04837365", "source": "WHO XML import", "relevant": null, "identifiers": { "nct": "NCT04837365" }, "categories": [], "export_date": "2024-05-04T00:00:00Z", "internal_number": "13154658", "last_refreshed_on": "2023-07-03", "scientific_title": "Impact of Neuropsychological Disorders on Visual Exploration, Walking Initiation and Walking in Multiple Sclerosis", "primary_sponsor": "Lille Catholic University", "retrospective_flag": "Yes", "date_registration": null, "source_register": "ClinicalTrials.gov", "recruitment_status": "Recruiting", "other_records": "No", "inclusion_agemin": "18 Years", "inclusion_agemax": "55 Years", "inclusion_gender": "All", "date_enrollement": "2021-05-21", "target_size": "20", "study_type": "Interventional", "study_design": "Allocation: Non-Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).", "phase": "N/A", "countries": "France", "contact_firstname": ";", "contact_lastname": "Caroline Massot, MD;Amélie Lansiaux, MD, PhD", "contact_address": null, "contact_email": ";[email protected]", "contact_tel": ";+33 3 20 22 52 69", "contact_affiliation": "GHICL;", "inclusion_criteria": "<br> Inclusion Criteria:\r<br>\r<br> - Understanding and able to speak French\r<br>\r<br> - Carriers of MS with relapsing remitting form (RRMS-RR) with an EDSS <4\r<br>\r<br> - No significant motor, cerebellar or somesthesia disorders of the upper limbs or visual\r<br> disturbances (side to a visual EDSS <2)\r<br>\r<br> - Absence of corticosteroid intake in the last four weeks\r<br>\r<br> - Benefiting from health insurance coverage\r<br>\r<br> - Not showing any flare-ups or worsening of the disease in the last 6 weeks\r<br>\r<br> - No botulinum toxin injection for more than 4 months\r<br>\r<br> Exclusion Criteria:\r<br>\r<br> - People with previous neurological pathologies, head trauma with loss of consciousness,\r<br> psychiatric pathologies, serious general ailments, perceptual or dysarthric disorders\r<br> preventing verbal communication or reading,\r<br>\r<br> - Treatment with psychotropic drugs (except benzodiazepines and hypnotics).\r<br>\r<br> - Refusal to participate after clear and fair information about the study.\r<br>\r<br> - Adults under tutorship, curatorship or safeguard of justice\r<br>\r<br> - With orthopedic treatment influencing walking\r<br>\r<br> - Pregnant woman\r<br>", "exclusion_criteria": null, "condition": "Multiple Sclerosis", "intervention": "Other: Three dimensional gait analysis with eyetracking", "primary_outcome": "Step length (in m);Walking speed (in m.s-1);Range of motion in the lower limbs in degrees;Cadence of walking (in cycles.min-1)", "secondary_outcome": "Ocular fixation time (measured in ms);Muscle contractions determined by the electromyogram (EMG) (mV);Displacements (in mm) during walking;Acceleration (in mm.s-2) during walking;Joint angles", "secondary_id": "RC-P00108", "source_support": "Please refer to primary and secondary sponsors", "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 40, "title": "Effect of Disease Modifying Therapy on Antibody Response to COVID19 Vaccination in Multiple Sclerosis", "summary": "Conditions: Multiple Sclerosis; Covid19Intervention: Sponsor : St. Barnabas Medical CenterRecruiting ", "published_date": "2021-04-07T16:00:00Z", "discovery_date": "2021-04-08T11:57:29Z", "link": "https://clinicaltrials.gov/ct2/show/NCT04834401?cond=Multiple+Sclerosis&amp;sfpd_d=14&amp;sel_rss=new14", "source": "Clinical Trials.gov", "relevant": null, "identifiers": { "nct": "NCT04834401" }, "categories": [], "export_date": null, "internal_number": null, "last_refreshed_on": null, "scientific_title": null, "primary_sponsor": null, "retrospective_flag": null, "date_registration": null, "source_register": null, "recruitment_status": null, "other_records": null, "inclusion_agemin": null, "inclusion_agemax": null, "inclusion_gender": null, "date_enrollement": null, "target_size": null, "study_type": null, "study_design": null, "phase": null, "countries": null, "contact_firstname": null, "contact_lastname": null, "contact_address": null, "contact_email": null, "contact_tel": null, "contact_affiliation": null, "inclusion_criteria": null, "exclusion_criteria": null, "condition": null, "intervention": null, "primary_outcome": null, "secondary_outcome": null, "secondary_id": null, "source_support": null, "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 41, "title": "Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS", "summary": "Condition: Multiple SclerosisIntervention: Sponsor : University Hospital, Strasbourg, FranceRecruiting ", "published_date": "2021-02-26T00:00:00Z", "discovery_date": "2021-04-08T11:57:29Z", "link": "https://clinicaltrials.gov/show/NCT04838015", "source": "WHO XML import", "relevant": null, "identifiers": { "nct": "NCT04838015" }, "categories": [ { "category_id": 8, "category_description": "", "category_name": "Ocrelizumab", "category_slug": "ocrelizumab", "category_terms": [ "ocrelizumab", "ocrevus" ], "article_count": 232 } ], "export_date": "2024-05-04T00:00:00Z", "internal_number": "10837273", "last_refreshed_on": "2021-04-19", "scientific_title": "Retrospective Study on Registry Data to Evaluate the Impact of Ocrelizumab Used in Routine Care in Patients With RRMS", "primary_sponsor": "University Hospital, Strasbourg, France", "retrospective_flag": "No", "date_registration": null, "source_register": "ClinicalTrials.gov", "recruitment_status": "Recruiting", "other_records": "No", "inclusion_agemin": "18 Years", "inclusion_agemax": "N/A", "inclusion_gender": "All", "date_enrollement": "2020-11-13", "target_size": "250", "study_type": "Observational", "study_design": null, "phase": null, "countries": "France", "contact_firstname": ";", "contact_lastname": "Nicolas COLLONGUES, MD;Nicolas COLLONGUES, MD", "contact_address": null, "contact_email": "[email protected];[email protected]", "contact_tel": "33 3 88 12 87 33;33 3 88 12 87 33", "contact_affiliation": null, "inclusion_criteria": "<br> Inclusion criteria:\r<br>\r<br> - Major subject (=18 years old)\r<br>\r<br> - Suffering from relapsing-remitting MS (RRMS)\r<br>\r<br> - Supported in a neurology department at Strasbourg or Nancy University Hospital between\r<br> 10/01/2018 and 11/31/2020.\r<br>\r<br> - Treated with ocrelizumab 600mg every 6 months during the period from 01/10/2018 to\r<br> 01/05/2020.\r<br>\r<br> - Have had an M0, M3 / M6 and M12 MRI after initiation of treatment.\r<br>\r<br> - Subject not having expressed his opposition, after information, to the reuse of his\r<br> data for the purposes of this research\r<br>\r<br> Exclusion criteria:\r<br>\r<br> - Subject having expressed opposition to participating in the study\r<br>\r<br> - Primary progressive multiple sclerosis (MS-PP), secondarily progressive (MS-SP)\r<br>\r<br> - Subject not meeting all the inclusion criteria\r<br>\r<br> - Impossibility of providing the subject with enlightened information (difficulties in\r<br> understanding the subject, etc.)\r<br>\r<br> - Subjects under safeguard of justice\r<br>\r<br> - Subject under guardianship or guardianship\r<br>", "exclusion_criteria": null, "condition": "Multiple Sclerosis", "intervention": null, "primary_outcome": "Retrospective study of the impact of ocrelizumab used in patients with multiple sclerosis", "secondary_outcome": null, "secondary_id": "8037", "source_support": "Please refer to primary and secondary sponsors", "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 42, "title": "Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab Treated With Ocrelizumab or Natalizumab", "summary": "Conditions: Multiple Sclerosis; Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases; Pathologic ProcessesIntervention: Device: Elecsys semi-quantitative Anti-SARS-CoV-2 antibody testSponsor : Dragonfly Research, LLCRecruiting ", "published_date": "2021-03-16T00:00:00Z", "discovery_date": "2021-04-08T11:57:29Z", "link": "https://clinicaltrials.gov/show/NCT04837651", "source": "WHO XML import", "relevant": null, "identifiers": { "nct": "NCT04837651" }, "categories": [ { "category_id": 7, "category_description": "", "category_name": "Natalizumab", "category_slug": "natalizumab", "category_terms": [ "natalizumab", "tysabri" ], "article_count": 300 }, { "category_id": 8, "category_description": "", "category_name": "Ocrelizumab", "category_slug": "ocrelizumab", "category_terms": [ "ocrelizumab", "ocrevus" ], "article_count": 232 } ], "export_date": "2024-05-04T00:00:00Z", "internal_number": "11240373", "last_refreshed_on": "2021-08-10", "scientific_title": "A Real World, Prospective, Single-center, Observational Study Comparing Humoral and T-Cell Responses to COVID-19 Vaccination in Multiple Sclerosis Patients Treated With Ocrelizumab or Natalizumab", "primary_sponsor": "Dragonfly Research, LLC", "retrospective_flag": "No", "date_registration": null, "source_register": "ClinicalTrials.gov", "recruitment_status": "Not recruiting", "other_records": "No", "inclusion_agemin": "18 Years", "inclusion_agemax": "55 Years", "inclusion_gender": "All", "date_enrollement": "2021-03-02", "target_size": "48", "study_type": "Observational", "study_design": null, "phase": null, "countries": "United States", "contact_firstname": "", "contact_lastname": "Joshua Katz, M.D.", "contact_address": null, "contact_email": null, "contact_tel": null, "contact_affiliation": "Dragonfly Research, LLC", "inclusion_criteria": "<br> Inclusion Criteria\r<br>\r<br> - Age 18-55\r<br>\r<br> - Diagnosis of multiple sclerosis (as per the revised 2017 criteria)\r<br>\r<br> - EDSS score of 0-5.5 inclusive\r<br>\r<br> - Has initiated ocrelizumab or natalizumab at least 6 months prior to study enrollment\r<br>\r<br> - For women of childbearing potential: agreement to remain abstinent or to use a highly\r<br> effective (99% efficacy or greater) contraceptive method\r<br>\r<br> - Individual must be able to provide consent, read/write/comprehend English language or\r<br> must be able to provide a consistent translator\r<br>\r<br> Exclusion Criteria\r<br>\r<br> - Previous infection with COVID-19, confirmed by FDA approved testing\r<br>\r<br> - Cognitive impairment limiting the ability to consent or complete study procedures\r<br>\r<br> - Currently pregnant, planning to become pregnant during the study period, or currently\r<br> breastfeeding\r<br>\r<br> - Any prior use of immunosuppressive or chemotherapy treatment (including, but not\r<br> limited to, cladribine, alemtuzumab, mycophenolate mofetil, cyclophosphamide,\r<br> methotrexate, azathioprine)\r<br>\r<br> - Prior treatment with a B-cell depleting therapy other than ocrelizumab within 12\r<br> months of first on-study infusion excluding standard ocrelizumab pre-treatment therapy\r<br>\r<br> - Use of systemic corticosteroid therapy within 12 weeks of screening (excluding\r<br> corticosteroid treatment given concurrently with ocrelizumab)\r<br>\r<br> - History of allergic reactions to vaccines\r<br>", "exclusion_criteria": null, "condition": "Multiple Sclerosis;Demyelinating Autoimmune Diseases, CNS;Autoimmune Diseases of the Nervous System;Nervous System Diseases;Demyelinating Diseases;Autoimmune Diseases;Immune System Diseases;Pathologic Processes", "intervention": "Device: Elecsys semi-quantitative Anti-SARS-CoV-2 antibody test;Device: T-Detect COVID T-cell blood test", "primary_outcome": "SARS-CoV-2 B-cell response;SARS-CoV-2 T-cell response", "secondary_outcome": null, "secondary_id": "VA26843", "source_support": "Please refer to primary and secondary sponsors", "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null }, { "trial_id": 37, "title": "The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Three Arms Randomized Trial", "summary": "Conditions: Multiple Sclerosis, Relapsing-Remitting; Pain, Chronic; Fatigue Syndrome, Chronic; KinesiophobiaInterventions: Behavioral: PMR: Progressive Muscle Relaxation; Behavioral: BRT:Benson Relaxation TechniqueSponsor : Hacettepe UniversityCompleted ", "published_date": "2021-05-04T00:00:00Z", "discovery_date": "2021-04-06T11:14:24Z", "link": "https://clinicaltrials.gov/show/NCT04833673", "source": "WHO XML import", "relevant": null, "identifiers": { "nct": "NCT04833673" }, "categories": [], "export_date": "2024-05-04T00:00:00Z", "internal_number": "10836988", "last_refreshed_on": "2021-04-19", "scientific_title": "The Effects of Relaxation Techniques on Pain, Fatigue and Kinesiophobia in Multiple Sclerosis Patients: A Three Arms Randomized Trial", "primary_sponsor": "Hacettepe University", "retrospective_flag": "No", "date_registration": null, "source_register": "ClinicalTrials.gov", "recruitment_status": "Not recruiting", "other_records": "No", "inclusion_agemin": "18 Years", "inclusion_agemax": "N/A", "inclusion_gender": "All", "date_enrollement": "2020-06-22", "target_size": "80", "study_type": "Interventional", "study_design": "Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Supportive Care. Masking: None (Open Label).", "phase": "N/A", "countries": "Turkey", "contact_firstname": "", "contact_lastname": "gulsah kesik, MSc", "contact_address": null, "contact_email": null, "contact_tel": null, "contact_affiliation": "research assisstant", "inclusion_criteria": "<br> Inclusion Criteria:\r<br>\r<br> - over the age of 18\r<br>\r<br> - having relapsing-remitting MS type and not had an attack during the study\r<br>\r<br> - not receiving any other complementary and integrative therapy during the research,\r<br>\r<br> - with an Expanded Disability Status Scale score of 5.5 and below,\r<br>\r<br> - volunteer to participate in study\r<br>\r<br> Exclusion Criteria:\r<br>\r<br> - having physical or mental health problems that can interfere with communication\r<br>\r<br> - having heart failure, COPD, asthma disease, renal failure, musculoskeletal problem\r<br> such as fracture, plaster cast, amputation, fibromyalgia, ankylosing spondylitis,\r<br> rheumatoid arthritis, deep anemia (hmg <8 mg / dl) or oncological diagnoses\r<br>\r<br> - not having undergone any surgical operation in the last 3 months\r<br>", "exclusion_criteria": null, "condition": "Multiple Sclerosis, Relapsing-Remitting;Pain, Chronic;Fatigue Syndrome, Chronic;Kinesiophobia", "intervention": "Behavioral: PMR: Progressive Muscle Relaxation;Behavioral: BRT:Benson Relaxation Technique", "primary_outcome": "Fatigue", "secondary_outcome": "Chronic Pain;Kinesiophobia", "secondary_id": "333", "source_support": "Please refer to primary and secondary sponsors", "ethics_review_status": null, "ethics_review_approval_date": null, "ethics_review_contact_name": null, "ethics_review_contact_address": null, "ethics_review_contact_phone": null, "ethics_review_contact_email": null, "results_date_completed": null, "results_url_link": null } ] }